HLS Therapeutics (TSE:HLS – Get Free Report) had its price objective dropped by investment analysts at Stifel Nicolaus from C$3.75 to C$3.25 in a research report issued to clients and investors on Tuesday, BayStreet.CA reports. Stifel Nicolaus’ price objective points to a potential upside of 4.84% from the stock’s previous close.
Separately, Raymond James cut their price objective on HLS Therapeutics from C$5.00 to C$4.00 in a research note on Friday, May 10th.
Get Our Latest Stock Report on HLS Therapeutics
HLS Therapeutics Price Performance
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
- Five stocks we like better than HLS Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- What is Put Option Volume?
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- How Technical Indicators Can Help You Find Oversold StocksÂ
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.